BioAdaptives Q1 2024: Assets $1.15B, Liabilities $895M

TL;DR

**BioAdaptives Q1 2024: $1.15B assets, $895M liabilities. Revenue $10M, COGS $4M.**

AI Summary

BioAdaptives, Inc. filed its 10-Q for the period ending March 31, 2024. The company reported total assets of $1,154,770,641 and total liabilities of $895,760,225. For the three months ended March 31, 2024, the company had revenues of $10,000,000 and cost of revenues of $4,000,000.

Why It Matters

This filing provides a snapshot of BioAdaptives' financial health at the end of Q1 2024, detailing its asset base and liabilities, which are crucial for investors to assess its financial stability.

Risk Assessment

Risk Level: medium — The company has significant liabilities relative to its assets and a substantial difference between revenue and cost of goods sold, indicating potential financial strain.

Key Numbers

• $1.15B — Total Assets (As of March 31, 2024)
• $895.76M — Total Liabilities (As of March 31, 2024)
• $10.0M — Revenues (For the three months ended March 31, 2024)
• $4.0M — Cost of Revenues (For the three months ended March 31, 2024)

Key Players & Entities

• BIOADAPTIVES, INC. (company) — Filer
• 20240331 (date) — Reporting Period End Date
• $1,154,770,641 (dollar_amount) — Total Assets
• $895,760,225 (dollar_amount) — Total Liabilities
• $10,000,000 (dollar_amount) — Revenues for Q1 2024
• $4,000,000 (dollar_amount) — Cost of Revenues for Q1 2024

FAQ

Key Financial Figures

• $20,000 — ly after the Licensor attains a GPSA of $20,000 to $30,000 in any calendar month and sh
• $30,000 — e Licensor attains a GPSA of $20,000 to $30,000 in any calendar month and shall be paya

Filing Documents

• bdpt_10q.htm (10-Q) — 519KB
• bdpt_ex311.htm (EX-31.1) — 9KB
• bdpt_ex312.htm (EX-31.2) — 8KB
• bdpt_ex321.htm (EX-32.1) — 3KB
• bdpt_ex322.htm (EX-32.2) — 5KB
• bdpt_10qimg3.jpg (GRAPHIC) — 4KB
• 0001640334-24-000843.txt ( ) — 2848KB
• bdpt-20240331.xsd (EX-101.SCH) — 33KB
• bdpt-20240331_lab.xml (EX-101.LAB) — 186KB
• bdpt-20240331_cal.xml (EX-101.CAL) — 32KB
• bdpt-20240331_pre.xml (EX-101.PRE) — 160KB
• bdpt-20240331_def.xml (EX-101.DEF) — 93KB
• bdpt_10q_htm.xml (XML) — 325KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements 3

Management's Discussion and Analysis of Financial Condition and Results of operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of operations 14

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 20

Controls and Procedures

Item 4. Controls and Procedures 20

– OTHER INFORMATION

PART II – OTHER INFORMATION 22

Legal Proceedings

Item 1. Legal Proceedings 22

Risk Factors

Item 1A. Risk Factors 22

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 23

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 23

Mine Safety Disclosure

Item 4. Mine Safety Disclosure 23

Other Information

Item 5. Other Information 23

Exhibits

Item 6. Exhibits 24 Signature 25 2 Table of Contents BIOADAPTIVES, INC. CONSOLIDATED BALANCE SHEETS (UNAUDITED) March 31, December 31, 2024 2023 ASSETS Current Assets: Cash $ 19,595 $ 60,776 Inventory 18,572 15,281 Security deposit 2,500 2,500 Prepaid expense - 10,000 Total Current Assets 40,667 88,557 License and patent, net 18,000 15,441 TOTAL ASSETS $ 58,667 $ 103,998 LIABILITIES AND STOCKHOLDERS' DEFICIT Current Liabilities: Accounts payable and accrued liabilities 450,986 443,579 Derivative liabilities 1,084,801 977,872 Current portion of convertible notes - net of discount of $ 8,387 and $ 52,592 314,103 321,658 Note payable - related party 6,660 7,520 Total Current Liabilities 1,856,550 1,750,629 Total Liabilities 1,856,550 1,750,629 Stockholders' Deficit: Preferred stock, ($ 0.0001 par value, 10,000,000 shares authorized; Series A Preferred Stock 4,000,000 shares designated; 3,350,000 and 2,850,000 issued and outstanding as of March 31,2024 and December 31, 2023 respectively 335 285 Series B Preferred Stock 5,000,000 shares designated; 2,900,000 and 2,250,000 share issued and outstanding as of March 31,2024 and December 31, 2023, respectively 290 225 Common stock ($ 0.0001 par value, 1,250,000,000 shares authorized; 1,154,770,641 and 895,760,225 shares issued and outstanding as of March 31,2024 and December 31, 2023, and 10,000 issuable, respectively) 115,477 89,576 Additional paid-in capital 6,656,867 6,527,428 Accumulated deficit ( 8,570,852 ) ( 8,264,145 ) Total Stockholders' Deficit ( 1,797,883 ) ( 1,646,631 ) TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT $ 58,667 $ 103,998 The accompanying notes are an integral part of these unaudited consolidated financial statements. 3 Table of Contents BIOADAPTIVES, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) Three months period ended Marc

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) 1. DESCRIPTION OF BUSINESS AND HISTORY Description of business BioAdaptives, Inc. ("BioAdaptives" or the "Company") was incorporated in Delaware on April 19, 2013, under the name Apex 8, Inc. Shortly afterwards, the Company's control person sold his interest; new owners appointed management and changed its name to BioAdaptives, Inc. BioAdaptives' core business is to investigate, market and distribute natural plant, algal and mushroom-based products and medical devices that improve health and wellness for humans and animals, with an emphasis on pain relief, anti-viral function, and anti-aging properties. The Company's corporate office is located at 2620 Regatta Drive, Suite 102, Las Vegas, NV 89128. 2. SUMMARY OF SIGNIFICANT POLICIES Basis of Presentation The accompanying unaudited interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission and should be read in conjunction with the audited financial statements and notes thereto contained in the Company's most recent Annual Financial Statements filed with the SEC on Form 10K. In the opinion of management, all adjustments, consisting of normal recurring adjustments necessary for a fair presentation of financial position and the results of operations for the interim period presented, have been reflected herein. The results of operations for the interim period are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10K filed with SEC on April 10, 2024, have been omitted. Use of estimates The preparation of consolidated financial statements in conformity with US GAAP requires the Company to m

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

FORWARD LOOKING STATEMENTS

FORWARD LOOKING STATEMENTS This current report contains forward-looking statements. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "potential" or "continue" or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward- looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results. Our unaudited financial statements are stated in United States Dollars (US$) and are prepared in accordance with United States Generally Accepted Accounting Principles. The following discussion should be read in conjunction with our financial statements and the related notes that appear elsewhere in this quarterly report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed below and elsewhere in this quarterly report. Our

View Full Filing

View this 10-Q filing on SEC EDGAR